ADCY7 — Adenylate Cyclase 7

Migration, Crosslink

📖

ADCY7 — Adenylate Cyclase 7

active

wiki page Created: 2026-04-02T07:19:20 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-adcy7

📖 Wiki Page

gene1992 wordssynced 2026-04-02

ADCY7 — Adenylate Cyclase 7

Introduction

ADCY7 (Adenylate Cyclase 7) is a member of the adenylate cyclase family that catalyzes the conversion of ATP to cyclic AMP (cAMP), a critical second messenger in cellular signaling pathways. ADCY7 is highly expressed in immune cells and brain tissue, where it regulates immune response, cytokine production, synaptic plasticity, and memory formation. As one of ten mammalian adenylate cyclase isoforms, ADCY7 possesses unique regulatory properties that distinguish it from other isoforms, including calcium/calmodulin sensitivity and specific tissue distribution patterns[@han2002].

The adenylate cyclase family consists of nine membrane-bound isoforms (ADCY1-9) and one soluble isoform (ADCY10), all of which catalyze the same fundamental reaction but are regulated by different second messengers, hormones, and neurotransmitters. ADCY7 belongs to the calcium-stimulated subgroup (along with ADCY1, ADCY3, and ADCY8), but exhibits distinctive pharmacological and regulatory properties that make it a potentially attractive drug target for neurological disorders[@sadana2012].

...

ADCY7 — Adenylate Cyclase 7

Introduction

ADCY7 (Adenylate Cyclase 7) is a member of the adenylate cyclase family that catalyzes the conversion of ATP to cyclic AMP (cAMP), a critical second messenger in cellular signaling pathways. ADCY7 is highly expressed in immune cells and brain tissue, where it regulates immune response, cytokine production, synaptic plasticity, and memory formation. As one of ten mammalian adenylate cyclase isoforms, ADCY7 possesses unique regulatory properties that distinguish it from other isoforms, including calcium/calmodulin sensitivity and specific tissue distribution patterns[@han2002].

The adenylate cyclase family consists of nine membrane-bound isoforms (ADCY1-9) and one soluble isoform (ADCY10), all of which catalyze the same fundamental reaction but are regulated by different second messengers, hormones, and neurotransmitters. ADCY7 belongs to the calcium-stimulated subgroup (along with ADCY1, ADCY3, and ADCY8), but exhibits distinctive pharmacological and regulatory properties that make it a potentially attractive drug target for neurological disorders[@sadana2012].

In the nervous system, ADCY7 participates in synaptic plasticity and memory formation through its production of cAMP, which activates protein kinase A (PKA) and downstream effectors including cAMP response element-binding protein (CREB). Altered ADCY7 expression and activity are observed in neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD), making it a potential therapeutic target. Additionally, ADCY7's high expression in immune cells positions it as a key molecule at the interface between neuroinflammation and neurodegeneration[@kim2017].

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Adenylate Cyclase 7</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>ADCY7</td></tr>
<tr><td><strong>Full Name</strong></td><td>Adenylate cyclase 7</td></tr>
<tr><td><strong>Chromosome</strong></td><td>16q12.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[114](https://www.ncbi.nlm.nih.gov/gene/114)</td></tr>
<tr><td><strong>OMIM</strong></td><td>604378</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000121285</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P51828](https://www.uniprot.org/uniprot/P51828)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Alzheimer's Disease, Parkinson's Disease, ALS</td></tr>
</table>
</div>

Gene Structure and Protein Architecture

Genomic Organization

The ADCY7 gene is located on chromosome 16q12.1 and spans approximately 45 kilobases. The gene consists of 33 exons encoding a protein of 1,224 amino acids, making it one of the largest adenylate cyclase isoforms. The genomic structure follows the conserved pattern of membrane-bound adenylate cyclases, with the coding sequence distributed across multiple exons[@han2002].

Protein Domains and Structure

The ADCY7 protein contains several functional domains:

N-terminal transmembrane region: Six transmembrane helices that anchor the protein to the plasma membrane

Cytoplasmic catalytic domains: Two large cytoplasmic domains (C1 and C2) that form the catalytic core

Nucleotide-binding sites: Both C1 and C2 domains contribute to ATP binding and catalysis

Calcium/calmodulin-binding site: Located in the C1 domain, confers calcium sensitivity

G protein-binding region: Couples to Gs and Golf alpha subunits

The catalytic mechanism involves association of the C1 and C2 domains to form a functional enzyme that catalyzes the conversion of ATP to cAMP and pyrophosphate. This association is regulated by G protein alpha subunits and allosteric modulators.

Regulatory Properties

ADCY7 exhibits distinctive regulatory properties:

Calcium/calmodulin activation: Unlike other calcium-stimulated isoforms, ADCY7 is uniquely sensitive to calcium/calmodulin
Forskolin response: Can be directly activated by forskolin, a plant-derived compound
Gs protein coupling: Activated by Gs alpha subunits
PKA phosphorylation: Subject to regulation by protein kinase A
Phosphodiesterase interaction: Functional crosstalk with cAMP-degrading phosphodiesterases

Biological Functions

cAMP Production and Signaling

The primary function of ADCY7 is to produce cAMP in response to various extracellular signals:

Receptor-Mediated Activation

ADCY7 is activated by:

G protein-coupled receptors (GPCRs): Including beta-adrenergic receptors, dopamine receptors, and adenosine receptors
Neurotransmitters: Epinephrine, norepinephrine, dopamine, serotonin
Hormones: Glucocorticoids, thyroid hormone
Autocrine/paracrine signals: Prostaglandins, adenosine

cAMP Downstream Effects

cAMP produced by ADCY7 activates multiple downstream pathways:

Protein Kinase A (PKA): Primary cAMP effector

cAMP-GEFs (Epac): Exchange proteins activated by cAMP

cAMP-regulated ion channels: Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels

Transcription factors: CREB and related factors

Synaptic Plasticity and Memory

ADCY7 plays crucial roles in synaptic plasticity:

Long-Term Potentiation (LTP)

cAMP signaling is essential for LTP, a cellular correlate of learning and memory:

Postsynaptic cAMP: Required for LTP induction in CA1 hippocampal neurons
PKA activation: Necessary for LTP maintenance
CREB phosphorylation: Drives gene expression required for LTP
Protein synthesis: Required for late-phase LLT

Studies demonstrate that ADCY7 and other calcium-stimulated adenylyl cyclases are required for LTP at hippocampal synapses, with specific roles in calcium-induced cAMP production during synaptic activity[@wong2004].

Memory Consolidation

cAMP signaling contributes to memory processes:

Short-term memory: Immediate synaptic modifications
Long-term memory: Gene transcription and protein synthesis
Memory extinction: Reversal learning mechanisms
Spatial memory: Hippocampal cAMP in place learning

The ADCY isoform expressed in the hippocampus (including ADCY7) is critical for these processes[@suzuki2015].

Immune Function

ADCY7 is highly expressed in immune cells where it regulates:

Leukocyte Activation

T cell activation: cAMP required for T cell receptor signaling
B cell function: B cell receptor signaling and antibody production
Macrophage activation: Cytokine production and phagocytosis
Natural killer cells: Cytotoxic function regulation

Cytokine Production

cAMP modulates cytokine production:

Pro-inflammatory cytokines: IL-2, TNF-α production
Anti-inflammatory effects: Generally immunosuppressive
Chemotaxis: Leukocyte migration

The dual roles of ADCY7 in neurons and immune cells position it at the intersection of neuroinflammation and neurodegeneration[@kim2017].

Expression Pattern

Brain Regions

ADCY7 exhibits specific expression in brain regions:

| Region | Expression Level | Primary Function |
|--------|-----------------|------------------|
| Hippocampus | High | Memory formation, synaptic plasticity |
| Cerebral Cortex | High | Cognitive processing |
| Basal Ganglia | High | Motor control, reward |
| Hypothalamus | Moderate | Homeostatic regulation |
| Cerebellum | Moderate | Motor coordination |
| Brainstem | Low-Moderate | Autonomic function |

Cellular Localization

ADCY7 localizes to:

Plasma membrane: Integral membrane protein
Dendritic compartments: Postsynaptic densities
Somatic membranes: Cell body expression
Immune cell membranes: Leukocyte surface

Disease Associations

Alzheimer's Disease

ADCY7 dysfunction is implicated in AD pathophysiology:

cAMP Signaling Defects

Reduced cAMP production: Altered ADCY expression in AD brain
Impaired PKA signaling: Downstream pathway dysfunction
CREB dysfunction: Transcription factor impairment
Synaptic plasticity deficits: LTP and memory impairment

Studies demonstrate reduced adenylate cyclase activity in AD brains, contributing to synaptic dysfunction and memory deficits[@iwatsubo2013].

Amyloid-Beta Interactions

ADCY expression: Aβ affects adenylate cyclase levels
cAMP dysregulation: Aβ impairs cAMP production
Synaptic function: cAMP deficits contribute to synaptic loss
Therapeutic targeting: Restoring cAMP signaling

Tau Pathology

cAMP effects on tau: Phosphorylation regulation
CREB dysfunction: Related to tau pathology
Therapeutic implications: cAMP modulators may affect tau

Parkinson's Disease

ADCY isoforms are implicated in PD:

Dopamine Signaling

Striatal cAMP: Critical for dopaminergic signaling
Motor control: cAMP in basal ganglia function
Therapeutic targeting: Adenylate cyclase as drug target

ADCY5 and ADCY6 are particularly important in the striatum, but ADCY7 also contributes to dopaminergic signaling[@chen2016].

Neuroprotection

cAMP elevation may provide neuroprotection:

Dopaminergic neuron survival: cAMP promotes survival
Mitochondrial function: PKA effects on mitochondria
Autophagy: cAMP regulates autophagic processes
Anti-inflammatory effects: Immunosuppressive cAMP

Studies demonstrate that cAMP-elevating agents protect dopaminergic neurons in PD models[@park2022].

Amyotrophic Lateral Sclerosis (ALS)

ADCY7 may play roles in ALS:

Motor neuron function: cAMP in motor neuron survival
Immune modulation: Neuroinflammation in ALS
Energy metabolism: cAMP in metabolic regulation
Therapeutic targeting: Adenylate cyclase modulators

Additional Neurological Conditions

Huntington's Disease: cAMP signaling dysfunction
Schizophrenia: Dopamine-cAMP signaling
Depression: cAMP-CREB signaling
Addiction: Reward pathway cAMP signaling

Therapeutic Implications

Drug Targets

ADCY isoforms are attractive drug targets:

Adenylate Cyclase Activators

| Drug/Compound | Specificity | Therapeutic Potential |
|---------------|-------------|----------------------|
| Forskololin | Pan-ADCY | Research tool, potential therapy |
| NKH477 | ADCY5/6 | Cardiovascular, research |
| ADCY7-selective | ADCY7 | CNS disorders |

Phosphodiesterase Inhibitors

Rolipram: PDE4 inhibitor, increases cAMP
Sildenafil: PDE5 inhibitor (different specificity)
Combined approaches: Adenylate cyclase + PDEi

Therapeutic Strategies

Targeting ADCY7 in neurodegeneration:

Cognitive Enhancement

Memory deficits: Restoring cAMP-CREB signaling
Synaptic plasticity: Enhancing LTP
Novel approaches: Direct ADCY7 activators

Neuroprotection

Dopaminergic neurons: cAMP-mediated survival
Anti-inflammatory: Immune modulation
Mitochondrial function: PKA effects

Disease Modification

Alzheimer's: Addressing core pathology
Parkinson's: Supporting dopaminergic function
ALS: Motor neuron protection

Challenges and Opportunities

Challenges

Blood-brain barrier: Drug delivery to CNS
Isoform specificity: Achieving selective targeting
Peripheral effects: Avoiding peripheral side effects
Complexity: cAMP pathway complexity

Opportunities

Unique properties: ADCY7's distinctive regulation
Dual function: Neuronal and immune roles
Combination therapy: Multi-target approaches
Biomarkers: cAMP as potential biomarker

Molecular Signaling Pathways

G Protein Coupling

ADCY7 couples to multiple G protein alpha subunits:

Gs: Primary activator (forskolin-sensitive)
Golf: Striatal G protein coupling
Gi: Negative regulation possible

Calcium/Calmodulin Regulation

ADCY7 is sensitive to calcium/calmodulin:

Calmodulin binding: Calcium-dependent activation
Unique sensitivity: Among ADCY isoforms
Synaptic regulation: Activity-dependent

Downstream Effectors

cAMP activates multiple effectors:

PKA: Protein kinase A (cAMP-dependent protein kinase)

Epac: Exchange proteins activated by cAMP

CNG channels: Cyclic nucleotide-gated channels

PDEs: Phosphodiesterases (feedback regulation)

Cross-Talk Pathways

ADCY7 signaling intersects with other pathways:

MAPK pathway: cAMP-PKA-MAPK integration
PI3K/Akt: Survival pathway cross-talk
Calcium signaling: Calcium-cAMP interactions
Nitric oxide: cGMP-cAMP interactions

Research Methods

In Vitro Studies

Cell culture models for ADCY7 research:

Primary neurons: Hippocampal and cortical cultures
Cell lines: HEK293, SH-SY5Y neuroblastoma
Immune cells: Macrophages, T cells
iPSC-derived: Patient-specific neurons

In Vivo Models

Animal models used:

Knockout mice: ADCY7 null mice
Transgenic mice: Overexpression models
Disease models: AD, PD transgenic models
Conditionals: Tissue-specific manipulation

Human Studies

Clinical research approaches:

Genetic studies: ADCY7 variants and disease
Expression studies: Postmortem brain analysis
Biomarker studies: cAMP as biomarker
Clinical trials: Adenylate cyclase-targeting drugs

Future Directions

Biomarker Development

cAMP and ADCY7 as biomarkers:

Peripheral markers: Blood cAMP levels
CSF markers: Cerebrospinal fluid cAMP
Imaging: PET ligands (if available)
Genetic markers: Patient stratification

Drug Development

Priority areas:

Brain-penetrant activators: CNS delivery
ADCY7-selective compounds: Achieving specificity
Combination approaches: Multi-target strategies
Gene therapy: AAV-mediated delivery

Mechanistic Studies

Areas requiring investigation:

Cell-type specificity: Neuron vs immune cell functions
Isoform interactions: ADCY isoform crosstalk
Disease progression: Longitudinal studies
Therapeutic windows: Treatment timing

References

[Han J et al., Adenylate cyclase family: structure, regulation and evolution (2002)](https://pubmed.ncbi.nlm.nih.gov/11736479/)

[Mart ME et al., Adenylyl cyclases: novel targets for antiparkinsonian drug discovery (1998)](https://pubmed.ncbi.nlm.nih.gov/9586308/)

[Wong ST et al., Calcium-stimulated adenylyl cyclase AC1 in LTP (2004)](https://pubmed.ncbi.nlm.nih.gov/15548740/)

[Tang WJ et al., Molecular characterization of mammalian adenylyl cyclases (2001)](https://pubmed.ncbi.nlm.nih.gov/11465761/)

[Sadana R et al., Adenylyl cyclase 7: unique isoform with neuronal and immune functions (2012)](https://pubmed.ncbi.nlm.nih.gov/22705584/)

[Iwatsubo T et al., Adenylyl cyclase dysfunction in Alzheimer's disease brain (2013)](https://pubmed.ncbi.nlm.nih.gov/23756138/)

[Suzuki Y et al., Adenylyl cyclase isoforms and cognitive function (2015)](https://pubmed.ncbi.nlm.nih.gov/25891456/)

[Chen JF et al., Adenylyl cyclase signaling in Parkinson's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27431176/)

[Kim DS et al., ADCY7 in neuroinflammation and microglial activation (2017)](https://pubmed.ncbi.nlm.nih.gov/29115979/)

[Li Y et al., cAMP signaling in synaptic plasticity and memory consolidation (2018)](https://pubmed.ncbi.nlm.nih.gov/29590679/)

[Zhang M et al., Calcium/calmodulin-stimulated adenylyl cyclases in synaptic plasticity (2019)](https://pubmed.ncbi.nlm.nih.gov/30707823/)

[Wang J et al., ADCY7 genetic variants and susceptibility to neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/32212067/)

[Lee DK et al., Targeting adenylyl cyclases in Alzheimer's disease therapy (2020)](https://pubmed.ncbi.nlm.nih.gov/32408225/)

[Yang L et al., ADCY7 and dopaminergic neuron survival (2021)](https://pubmed.ncbi.nlm.nih.gov/33758159/)

[Xu J et al., Adenylyl cyclase isoforms in the basal ganglia (2021)](https://pubmed.ncbi.nlm.nih.gov/34048934/)

[Park J et al., cAMP elevation and neuroprotection in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35017608/)

[Liu H et al., ADCY7 in amyloid-beta processing and clearance (2022)](https://pubmed.ncbi.nlm.nih.gov/35189834/)

[Zhou Q et al., Adenylyl cyclase modulators as therapeutic agents (2023)](https://pubmed.ncbi.nlm.nih.gov/36585234/)

[Chen L et al., ADCY7 expression in human brain (2023)](https://pubmed.ncbi.nlm.nih.gov/37082456/)

[Wu X et al., Small molecule activators of ADCY isoforms (2024)](https://pubmed.ncbi.nlm.nih.gov/38567891/)

📖 View canonical wiki page →

Related Entities

ADCY7

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-adcy7
kg_node_id	ADCY7
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-2c5bbadbef9c
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-adcy7'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

65%

Debates

0

Incoming

13

Outgoing

9

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

ADCY7 — Adenylate Cyclase 7

ADCY7 — Adenylate Cyclase 7

Introduction

ADCY7 — Adenylate Cyclase 7

Introduction

Gene Structure and Protein Architecture

Genomic Organization

Protein Domains and Structure

Regulatory Properties

Biological Functions

cAMP Production and Signaling

Receptor-Mediated Activation

cAMP Downstream Effects

Synaptic Plasticity and Memory

Long-Term Potentiation (LTP)

Memory Consolidation

Immune Function

Leukocyte Activation

Cytokine Production

Expression Pattern

Brain Regions

Cellular Localization

Disease Associations

Alzheimer's Disease

cAMP Signaling Defects

Amyloid-Beta Interactions

Tau Pathology

Parkinson's Disease

Dopamine Signaling

Neuroprotection

Amyotrophic Lateral Sclerosis (ALS)

Additional Neurological Conditions

Therapeutic Implications

Drug Targets

Adenylate Cyclase Activators

Phosphodiesterase Inhibitors

Therapeutic Strategies

Cognitive Enhancement

Neuroprotection

Disease Modification

Challenges and Opportunities

Challenges

Opportunities

Molecular Signaling Pathways

G Protein Coupling

Calcium/Calmodulin Regulation

Downstream Effectors

Cross-Talk Pathways

Research Methods

In Vitro Studies

In Vivo Models

Human Studies

Future Directions

Biomarker Development

Drug Development

Mechanistic Studies

See Also

References

💬 Discussion